We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-26.25%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$455M
AUM Growth
-$327M
Cap. Flow
-$168M
Cap. Flow %
-36.97%
Top 10 Hldgs %
79.01%
Holding
161
New
35
Increased
35
Reduced
40
Closed
40

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$28.9M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$5.02M
3
ESPR
Esperion Therapeutics
ESPR
+$1.86M
4
RSLS
ReShape Lifesciences Inc. Common Stock
RSLS
+$1.72M
5
LFWD icon
ReWalk Robotics
LFWD
+$1.65M

Top Sells

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$8.71M
2
XERS icon
Xeris Biopharma Holdings
XERS
+$5.7M
3
FOLD
Amicus Therapeutics
FOLD
+$1.87M
4
APTX
Aptinyx Inc. Common Stock
APTX
+$1.19M
5
VKTX icon
Viking Therapeutics
VKTX
+$1.09M

Sector Composition

Rank Sector Weight
1 Healthcare 21.24%
2 Technology 0.34%
3 Consumer Staples 0.21%
4 Financials 0.17%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRNE
151
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$0 ﹤0.01%
+84,536
New +$276K
GBT
152
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-1,312
Closed -$4.99M
HSTO
153
CALL
DELISTED
Histogen Inc. Common Stock
HSTO
– –
-2
Closed -$253K
NSPRW
154
DELISTED
InspireMD, Inc. Warrants
NSPRW
– –
-498,797
Closed -$1K
EIDX
155
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
– –
-76,740
Closed -$766K
RXIIW
156
DELISTED
RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021
RXIIW
– –
-195,259
Closed -$68K
CYTXW
157
DELISTED
Cytori Therapeutics Inc Warrant
CYTXW
– –
-37,793
Closed –
RIBT
158
DELISTED
RiceBran Technologies
RIBT
– –
-28,106
Closed -$807K
SPHS
159
PUT
DELISTED
Sophiris Bio, Inc.
SPHS
– –
-1,578
Closed -$440K
AIM
160
AIM ImmunoTech
AIM
$6.54M
– –
-260
Closed -$263K
3 4 5 6
7

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2018 Portfolio in Review

As of Q4 2018, Sabby Management held 161 positions worth $455M, down 42% from $782M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Sabby Management withdrew a net $168M in Q4 2018, closing 40 positions and reducing 40 holdings. Its most notable exit was Amicus Therapeutics, an estimated $1.87M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 15% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Sabby Management opened a new position in State Street SPDR S&P Biotech ETF worth $4.47M.

  • Sabby Management's largest Q4 2018 buy was State Street SPDR S&P Biotech ETF: 62,266 shares worth $4.47M.
  • Sabby Management added most to Biogen in Q4 2018, an estimated $28.9M increase.
  • Sabby Management's biggest Q4 2018 reduction was Nektar Therapeutics, cutting an estimated $8.71M.
  • Sabby Management fully exited Amicus Therapeutics in Q4 2018, selling an estimated $1.87M.
  • Sabby Management's ten largest holdings make up 79% of its $455M portfolio in Q4 2018.
  • Sabby Management opened 35 new positions and closed 40 in Q4 2018.
  • Sabby Management's portfolio value fell 42% quarter-over-quarter to $455M.

Based on Sabby Management's 13F filing for Q4 2018, filed 14 Feb 2019.